Internal Medicine, Infectious Disease · Fort Worth, TX
NPI
1801274477
Since 2015
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1025 College Ave
Fort Worth, TX, 76104
Phone (817) 810-9810
Groups this clinician bills Medicare through
Medicare paid, 2024
$220K
6,881 services
Medicare patients, 2024
470
Average age 73
Drug cost, 2024
$375K
1,045 prescriptions
Company payments, 2025
$1,774
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin B Golden was code 99232 (hospital e&m - subsequent), 1,404 times for 369 patients. In total Kevin B Golden billed 6,881 services in 31 codes, and Medicare paid $220K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-04-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,404 | 369 | $61.19 | $86K |
| 99214 Office E&M - Established | Office | 174 | 88 | $99.58 | $17K |
| 99223 Hospital E&M - Initial | Facility | 161 | 155 | $135.48 | $22K |
| 99213 Office E&M - Established | Office | 90 | 65 | $70.26 | $6,323 |
| 99222 Hospital E&M - Initial | Facility | 87 | 83 | $102.19 | $8,891 |
| 99233 Hospital E&M - Subsequent | Facility | 84 | 57 | $92.80 | $7,795 |
| 96365 Intravenous Infusion, Hydration | Office | 82 | 12 | $49.31 | $4,044 |
| 99205 Office E&M - New | Office | 18 | 18 | $161.52 | $2,907 |
By year: 2022 $222K for 18,669 services; 2023 $130K for 22,165 services; 2024 $220K for 6,881 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kevin B Golden prescribed most often to Medicare patients was Daptomycin, with 117 prescriptions and refills. In total Kevin B Golden wrote 1,045 Medicare prescriptions that cost $375K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Daptomycin Generic | 117 | 117 | 26 | $63K |
| Meropenem Generic | 89 | 89 | 19 | $21K |
| Doxycycline Hyclate Generic | 83 | 93 | 24 | $1,800 |
| Cefepime Hcl Generic | 60 | 60 | 15 | $7,913 |
| Ceftriaxone Ceftriaxone Sodium | 58 | 58 | 22 | $3,288 |
| Fosfomycin Tromethamine Generic | 44 | 44 | 12 | $9,126 |
| Ceftazidime Generic | 40 | 40 | Under 11 | $2,267 |
| Ertapenem Ertapenem Sodium | 39 | 39 | 16 | $17K |
| Cefazolin Sodium Generic | 33 | 33 | Under 11 | $2,290 |
| Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam | 31 | 31 | Under 11 | $8,568 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 29 | 29 | 12 | $699 |
| Cefdinir Generic | 28 | 28 | 14 | $604 |
| Micafungin Micafungin Sodium | 28 | 28 | Under 11 | $15K |
| Vancomycin Hcl Generic | 27 | 28 | Under 11 | $4,586 |
| Caspofungin Acetate Generic | 26 | 26 | Under 11 | $15K |
Brand drugs: - claims; generic drugs: 925 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin B Golden $1,774 ($1,774 in general payments such as food, travel and fees) from 14 companies. The largest payer was ViiV Healthcare Company with $597.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 24 | $597 |
| Insmed, Inc. INSM | 12 | $248 |
| Gilead Sciences, Inc. GILD | 9 | $188 |
| Merck Sharp & Dohme LLC MRK | 7 | $144 |
| CSL Behring CSL.AX | 4 | $106 |
| Theratechnologies Inc. THTX | 4 | $102 |
| Abbvie Inc. ABBV | 5 | $94.31 |
| Paratek Pharmaceuticals, Inc. | 4 | $89.72 |
| Melinta Therapeutics, LLC | 4 | $82.02 |
| Aimmune Therapeutics, Inc. | 2 | $39.72 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.